FDA — authorised 18 January 1966
- Application: NDA012429
- Marketing authorisation holder: WAYLIS THERAP
- Local brand name: THIOGUANINE
- Indication: TABLET — ORAL
- Status: approved
FDA authorised 6-Thioguanine on 18 January 1966
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 18 January 1966; FDA has authorised it.
WAYLIS THERAP holds the US marketing authorisation.